Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic

Thrombosis and Haemostasis

Volumn 85, Issue 3, 2001, Pages 379-389

  Presta, L ^a   Sims, P ^a   Meng, Y G ^a   Moran, P ^a   Bullens, S ^a   Bunting, S ^a   Schoenfeld, J ^a   Lowe, D ^a   Lai, J ^a   Rancatore, P ^a   Iverson, M ^a   Lim, A ^a   Chisholm, V ^a   Kelley, R F ^a   Riederer, M ^a   Kirchhofer, D ^a  

^a GENENTECH INC   (United States)

Author keywords

Anticoagulants; Coagulation factor VII; Humanization; Thrombosis; Tissue factor

Indexed keywords

AMINO ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; PROTEIN ANTIBODY; THROMBOPLASTIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CHIMERA; CLONING; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG INHIBITION; DRUG POTENCY; FIBRIN DEPOSITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN VARIANT; VEIN BLOOD FLOW; VEIN THROMBOSIS;

EID: 0035083274     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615593     Document Type: Article

References (66)

1. The tissue factor pathway: How it has become a 'Prima Ballerina'
2. Biochemistry and physiology of blood coagulation
3. Biochemical and molecular aspects of the coagulation cascade
4. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque
5. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes
6. Macrophages, smooth muscle cells, and tissue factor in unstable angina
7. Identification of active tissue factor in human coronary atheroma
8. Tissue factor expression on macrophages in coronary plaques in patients with unstable angina
9. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques
10. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques
11. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques
12. Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis
13. Pathways of coagulation activation in situ in rheumatoid synovial tissue
14. Generation of tissue factor by patient monocytes: Correlation to thromboembolic complications
15. Postoperative elevation of human peripheral blood monocyte tissue factor coagulant activity
16. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries
17. Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis
18. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function
19. Tissue factor contributes to microvascular defects after focal cerebral ischemia
20. Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion
21. Tissue factor is expressed on monocytes during simulated extracorporeal circulation
22. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model
23. Sequential injury of the rabbit abdominal aorta induces intramural coagulation and luminal narrowing independent of intimal mass
24. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody
25. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees
26. Epitope location on tissue factor determines the anticoagulant potency of monoclonal anti-tissue factor antibodies
27. An anti-tissue factor monoclonal antibody which inhibits TF·VIIa complex is a potent anticoagulant in plasma
28. An unusual antibody that blocks tissue factor/factor VIIa function by inhibiting cleavage only of macromolecular substrates
29. The mechanism of an inhibitory antibody on TF-initiated blood coagulation revealed by the crystal structures of human tissue factor, Fab 5G9 and TF·5G9 complex
30. 166 of tissue factor with the 4-carboxyglutamate-rich domain of factor X
31. Influence of mutations in tissue factor on the fine specificity of macromolecular substrate activation
32. Lysine residues 165 and 166 are essential for the cofactor function of tissue factor
33. Cofactor residues lysine 165 and 166 are critical for protein substrate recognition by the tissue factor-factor VIIa protease complex
34. Tissue factor residues 157-167 are required for efficient proteolytic activation of factor X and factor VII
35. The tissue factor region that interacts with substrates factor IX and factor X
36. Recombinant antibodies for the diagnosis and therapy of human disease
37. The development of monoclonal antibodies for the therapy of cancer
38. GPIIb/IIIa antagonists: Pathophysiologic and therapeutic insights from studies of c7E3 Fab
39. Human antibodies by design
40. Humanization of an anti-p185HER2 antibody for human cancer therapy
41. Lipid association, but not the transmembrane domain, is required for tissue factor activity
42. Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside
43. Analysis of the factor VIIa binding site on human tissue factor: Effects of tissue factor mutations on the kinetics and thermodynamics of binding
44. Mammalian cell transient expression of tissue factor for the production of antigen
45. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for therapy of solid tumors and other disorders
46. X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling
47. Humanization of an anti-lymphocyte function-associated antigen (LFA-1) monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1
48. Rapid and efficient site-specific mutagenesis without phenotypic selection
49. Conformations of immunoglobulin hypervariable regions
50. The leucine zipper: A hypothetical structure common to a new class of DNA binding proteins
51. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule
52. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody
53. Intrachain disulfide bond in the core hinge region of human IgG4
54. Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model
55. Endothelial cells stimulated with tumor necrosis factor-α express varying amounts of tissue factor resulting in inhomogenous fibrin deposition in a native blood flow system
56. Immunologic quantification of fibrin in thrombi formed in flowing native human blood
57. Purification of recombinant human tissue factor
58. A human antibody that binds to the γ-carboxyglutamic acid domain of factor IX is a potent antithrombotic in vivo
59. Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformation of heavy-chain hypervariable loops
60. Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins
61. Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: Identification and effect on binding affinity
62. The protein data bank
63. Purification, sequence and crystallisation of an anti-tissue factor Fab and its use for the crystallization of tissue factor
64. Effects of genetic engineering on the pharmacokinetics of antibodies